Lab-on-a-Chip Market Outlook:
Lab-on-a-Chip Market size was valued at USD 7.54 billion in 2025 and is likely to cross USD 18.86 billion by 2035, registering more than 9.6% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of lab-on-a-chip is assessed at USD 8.19 billion.
Point-of-care testing enables rapid, on-site diagnostics, reducing reliance on centralized labs. Lab-on-a-chips, being compact and efficient, are essential in both developed and resource-limited settings. The growing demand for faster diagnostics in managing chronic diseases such as diabetes, cancer, and cardiovascular conditions, as well as during infectious diseases outbreaks, is driving their adoption. For instance, approximately 38.4 million people of all ages, or 11.6% of the U.S. population, had diabetes in 2021, according to CDC research published in May 2024. With precise results from minimal samples, lab-on-a-chips play a crucial role in early diagnosis, disease monitoring, and personalized treatment planning, fueling lab-on-a-chip market growth.
Additionally, innovations in microfluidics have significantly enhanced the performance of lab-on-a-chip, making them more efficient, accurate, and cost-effective. Sysmex Corporation introduced a point-of-care testing system in June 2023 that uses a special and exclusive microuidic technology to quickly determine antibiotic susceptibility in Europe. Advancements in material science and the integration of biosensors have allowed for more precise diagnostics and monitoring. Automation of complex laboratory processes on a single chip has expanded the applications of lab-on-a-chips across genomics, proteomics, and drug discovery. These innovations not only streamline laboratory workflows but also open new avenues for research and personalized healthcare, driving lab-on-a-chip market growth.
